Skip to main content
PUMA BIOTECHNOLOGY, INC. logo

PUMA BIOTECHNOLOGY, INC. — Investor Relations & Filings

Ticker · PBYI ISIN · US74587V1070 US Manufacturing
Filings indexed 1,055 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country US United States of America
Listing US PBYI

About PUMA BIOTECHNOLOGY, INC.

https://www.pumabiotechnology.com/

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. The company's primary commercial product is Nerlynx® (neratinib), an FDA-approved oral medication for certain types of breast cancer. Its clinical pipeline includes alisertib, an investigational drug being evaluated in clinical trials for small cell lung cancer and metastatic breast cancer. The company's mission is to develop and commercialize innovative products to enhance cancer care.

Recent filings

Filing Released Lang Actions
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Regulatory Filings
2026-05-07 English
ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Annual Report
2026-04-28 English
SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
Major Shareholding Notification
2026-03-27 English
10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated February 26, 2026. It announces the issuance of a press release containing financial results for the fourth quarter and fiscal year ended December 31, 2025. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and that the information is being furnished and not filed, indicating this document itself is an announcement rather than the full financial report. The document length is 3550 characters, which is relatively short and consistent with an announcement rather than a full earnings release or annual report. The key content is the announcement of financial results via a press release, which aligns with the definition of an Earnings Release (ER) as the initial announcement of quarterly/periodical financial results (key highlights only). Therefore, the appropriate classification is Earnings Release (ER).
2026-02-26 English
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Director's Dealing
2026-02-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.